JP2018500386A5 - - Google Patents

Info

Publication number

JP2018500386A5

JP2018500386A5 JP2017544990A JP2017544990A JP2018500386A5 JP 2018500386 A5 JP2018500386 A5 JP 2018500386A5 JP 2017544990 A JP2017544990 A JP 2017544990A JP 2017544990 A JP2017544990 A JP 2017544990A JP 2018500386 A5 JP2018500386 A5 JP 2018500386A5

Authority

JP

Japan

Prior art keywords

homodimer

administered

mammalian subject

composition

administration

Prior art date

2015-11-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000710 homodimer Substances 0.000 claims 37
• 239000000203 mixture Substances 0.000 claims 27
• 239000013538 functional additive Substances 0.000 claims 13
• 108090000765 processed proteins & peptides Proteins 0.000 claims 10
• 238000000034 method Methods 0.000 claims 9
• 230000002265 prevention Effects 0.000 claims 9
• 239000004480 active ingredient Substances 0.000 claims 8
• 238000009472 formulation Methods 0.000 claims 8
• 239000000178 monomer Substances 0.000 claims 8
• 239000008194 pharmaceutical composition Substances 0.000 claims 8
• 201000010099 disease Diseases 0.000 claims 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
• 208000002705 Glucose Intolerance Diseases 0.000 claims 2
• 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
• 206010022489 Insulin Resistance Diseases 0.000 claims 2
• 239000003472 antidiabetic agent Substances 0.000 claims 2
• 229940125708 antidiabetic agent Drugs 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
• 201000008980 hyperinsulinism Diseases 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 201000009104 prediabetes syndrome Diseases 0.000 claims 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 102400000321 Glucagon Human genes 0.000 claims 1
• 108060003199 Glucagon Proteins 0.000 claims 1
• 206010051161 Hyperglucagonaemia Diseases 0.000 claims 1
• 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
• 239000000654 additive Substances 0.000 claims 1
• 238000011260 co-administration Methods 0.000 claims 1
• 230000006806 disease prevention Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
• 229960004666 glucagon Drugs 0.000 claims 1
• 230000035880 hyperglucagonemia Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1